Metalloenzyme Inhibitors and Activators III
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 240
Special Issue Editors
Interests: medicinal chemistry; metallo-enzyme inhibitors; drug discovery; synthesis of biologically active compounds; fluorescent probes
Special Issues, Collections and Topics in MDPI journals
2. Interdepartmental Research Center “Nutraceuticals and Food for Health”, University of Pisa, 56100 Pisa, Italy
Interests: phytochemicals; polyphenols; nutraceuticals; bioactives; food waiste; olive oil; medicinal chemistry; synthetic chemistry; analytical chemistry; biological screening
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metalloenzymes represent a target of medicinal chemistry that has been extensively investigated in the last several decades. Since they are responsible for the regulation of a wide range of physiological processes, they are also involved in the development of many pathological conditions, including cancer, inflammation, microbial infections, and HIV/AIDS. Metalloenzymes are metalloproteins characterized by a functional metal ion that serves to promote catalysis. Achieving selectivity for a particular isoenzyme over other members of the same family is an issue that has hampered the clinical development of metalloenzyme inhibitors. Recent studies involving the resolution of enzyme crystal structures, site-directed mutagenesis of catalytic residues, and molecular modeling of catalytic domains have allowed for the synthesis of more selective agents.
This Special Issue aims to collect the recent advances in the inhibition of metalloenzymes such as carbonic anhydrases, matrix metalloproteinases (MMPs), ADAMs (A Disintegrin-like And Metalloproteinases), ADAMTSs (ADAM with Thrombospondin-like motifs), histone deacetylases (HDACs), angiotensin-converting enzyme (ACE), and HIV-1 integrase, among others. Particularly welcome are studies involving the development of small molecules but also exosite inhibitors, glycoconjugates, as well as protein–protein interaction (PPI) inhibitors.
Dr. Elisa Nuti
Dr. Doretta Cuffaro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug discovery
- synthesis
- structure–activity relationships
- metalloenzyme inhibitors
- carbonic anhydrase
- MMPs
- ADAMs
- ADAMTSs
- HDACs
- activators
